Browsing by Subject "Rhabdomyolysis"
Now showing items 1-6 of 6
-
Gender-specific Rhabdomyolysis risk in Alzheimer’s disease patients receiving memantine: a pharmacovigilance study
(Brac University, 2023-10)Alzheimer’s disease is a neurodegenerative disease. Using FDA Adverse Event Reporting System database, a pharmacovigilance study for gender specific rhabdomyolysis risk in memantine users was conducted between January ... -
A pharmacovigilance study of gender differences in rhabdomyolysis risk among donepezil users with alzheimer`s disease
(Brac University, 2023-10)Alzheimer’s disease is the most common disease for older patients marked by symptoms of dementia. This study was conducted for the pharmacovigilance investigation of donepezil related to adverse event rhabdomyolysis among ... -
A pharmacovigilance study on Donepezil: signal detection of rhabdomyolysis and death
(Brac University, 2023-02)Alzheimer’s disease is an age-related neurodegenerative disease that effects the cognitive ability of a person. The cholinesterase inhibitor “donepezil” is used to treat Alzheimer's disease. Donepezil has shown the greatest ... -
A pharmacovigilance study on Memantine: signal detection of Rhabdomyolysis and death
(Brac University, 2023-02)Alzheimer's Disease (AD) is a complex and common neurological disorder and dementia's leading cause. Memantine works to treat moderate to severe AD. This study focused on Food and Drug Administration Adverse Event Reporting ... -
Signal detection of Rhabdomyolysis and death for galantamine: a pharmacovigilance study
(Brac University, 2023-02)Galantamine is one of the common acetylcholinesterase inhibitors used to treat Alzheimer's disease, a neurodegenerative disorder. This study was conducted to determine the impact of galantamine on mortality rate and ... -
Signal detection of rhabdomyolysis and death for rivastigmine: a pharmacovigilance study
(Brac University, 2023-02)The following study utilized the Food and Drug Administration Adverse Event Reporting System (FAERS) database to determine the AChI inhibitor, rivastigmine’s effect on patient mortality as well as its side effect of ...
